GlassScriptPhysician profile
Saurabh Desai
NPI 1578626602
$9,671.97
in general payments reported to CMS, 2019-2025
49 companies · $1,665 in 2025
The $1,665 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,820 · 2020: $495 · 2021: $675 · 2022: $805 · 2023: $2,239 · 2024: $1,973 · 2025: $1,665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,877.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,585.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $956.06 | 2019-2025 | |
| Novo Nordisk INC | $841.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $664.18 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $514.31 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $456.34 | 2019-2024 | |
| Abbott Laboratories | $404.41 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $383.79 | 2019-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $338.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $322.65 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $289.07 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.12 | 2020-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $236.71 | 2022-2025 | Rexulti |
| Abbvie INC. | $233.93 | 2021-2025 | Ubrelvy, Qulipta, Creon |
| Sanofi-Aventis U.S. LLC | $217.55 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.